NeoSCORE II: three vs four cycles of neoadjuvant sintilimab + chemotherapy for squamous non-small-cell lung cancer

Xinyi Zhang,Miner Shao,Jie Yao,Lufeng Zhao,Lili Li,Mengyao Chen,Yixin Zhang,Huiying Liu,Zexin Chen,Baizhou Li,Zuqun Wu,Junqiang Fan,Fuming Qiu

DOI: https://doi.org/10.2217/fon-2024-0026

2024-02-16

Future Oncology

Abstract:Immune checkpoint inhibitors (ICIs) plus chemotherapy has demonstrated efficacy in resectable non-small-cell lung cancer (NSCLC), yet the optimal period of neoadjuvant immunochemotherapy is undetermined. In a phase II study (neoSCORE, NCT04459611), more neoadjuvant therapy cycles appeared to provide greater pathological remission, and patients with squamous NSCLC had a better major pathological response rate than those with nonsquamous NSCLC. Sintilimab, a monoclonal anti-PD-1 antibody, has shown encouraging antitumor activity and safety in multiple cancers, including NSCLC. Here, we describe the study design of neoSCORE II (NCT05429463), a randomized, open-label, multicenter phase III trial comparing the efficacy and safety of three cycles with four cycles of neoadjuvant sintilimab plus platinum-based chemotherapy in resectable stage IIA–IIIB squamous NSCLC. Trial registration number: NCT05429463 (ClinicalTrials.gov) NeoSCORE II: a phase 3 trial comparing the efficacy and safety of three cycles with four cycles of neoadjuvant sintilimab plus platinum-based chemotherapy in resectable stage IIA-IIIB squamous NSCLC. ClinicalTrials.gov: NCT05429463. #NSCLC #immunotherapy.

oncology